Zepbound vs. Mounjaro: Which GLP-1 Medication Delivers Better Outcomes?

Dr. Michael Brandwein
3 days ago
6 min read

For more information on our content creation process, view our Editorial Policy.

Key Takeaways:

Same ingredient, different approvals – Both Zepbound and Mounjaro contain tirzepatide, but Zepbound is FDA-approved for chronic weight management, while Mounjaro is approved for type 2 diabetes.
Weight loss outcomes – Clinical trials show Zepbound users achieve greater average weight loss (up to ~22%) compared with Mounjaro users (~15%), reflecting its weight-focused dosing protocols.
Coverage drives access – Insurance typically favors Mounjaro for diabetes, while Zepbound may face more restrictions for weight loss, making diagnosis and treatment goals key to prescribing decisions.

Targeting long-term weight management and diabetes control, both Zepbound and Mounjaro stand at the forefront of GLP-1-based treatments, but which one consistently yields stronger results?

Patients and providers alike have noticed that while these two medications share a common mechanism, their approval indications, dosing protocols, and efficacy rates hint at significant differences.

If you want to stay informed, understanding the subtleties between Zepbound and Mounjaro offers clarity.

At MyorThrive, we support informed choices through robust education and personalized weight loss solutions.

>> Also read: Foods to avoid on Ozempic diets

How Do Zepbound and Mounjaro Compare Across Key Categories?

Both Zepbound and Mounjaro are brand names for tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The compounds act by mimicking naturally occurring incretin hormones to enhance insulin secretion, reduce glucagon levels, slow gastric emptying, and suppress appetite.

While the active ingredient is identical in both treatments, their FDA-approved indications differ.

What are the Active ingredients & Mechanism of Action?

Both medications contain tirzepatide, a dual agonist for GIP and GLP-1 receptors, enhancing insulin release and improving satiety Ro 5Drugs.com 5Wikipedia 5.
The dual-targeted mechanism often results in more effective weight loss than GLP%u20111-only medications like semaglutide Investors 15Health 15BILD 15.

Are they both FDA-approved?

Yes, they are both FDA-approved but for different reasons:

Mounjaro: Approved for type 2 diabetes to improve glycemic control.
Zepbound: Approved for chronic weight management (BMI %u226530 kg/m² or %u226527 kg/m² with a weight-related condition like high blood pressure or OSA) and moderate to severe OSA in adults with obesity.

Which one is more efficient for weight loss?

In obese individuals without diabetes, Zepbound users achieved up to ~20.9% weight loss at 15 mg over 72 weeks.
Mounjaro has also shown substantial weight reduction-for instance, up to 12.8-14.7% in those with type 2 diabetes over the same period.
Clinical studies support that Zepbound users lose more weight than those on semaglutide-based therapies.

Target Population and Use Cases

The patient populations for Zepbound and Mounjaro intersect, although each drug targets different primary outcomes. Mounjaro is prescribed explicitly for blood glucose control in individuals with type 2 diabetes-and incidentally, it induces weight loss.

Zepbound, on the other hand, centers on weight management but also benefits glycemic parameters in overweight or obese individuals with or without diabetes.

Formulation and Dosing Convenience

Both medications are administered as once-weekly subcutaneous injections. They come in pre-filled, single-dose pens, which reduce dosing complexity. No differences in device format or administration frequency exist between the two options.

Side Effects & Safety Profile

Common adverse effects include gastrointestinal symptoms like nausea, vomiting, diarrhea, reduced appetite, and abdominal discomfort
There is also a boxed warning regarding potential thyroid tumors based on animal studies; it's important to discuss individual risks with your healthcare provider.

Regulatory Framework and Branding Strategy

Lilly markets tirzepatide under two different names for regulatory and strategic insurance coding purposes:
Zepbound is covered under the anti-obesity drug reimbursement framework and is classified for weight loss use.
Mounjaro is treated as a diabetes therapy by insurers and providers, impacting availability and prescription patterns.

Visual Appearance and Delivery Devices

Zepbound and Mounjaro use nearly identical delivery platforms. Pens from both brands feature color-coded caps to signify dose strength, auto-injection mechanisms, and built-in safety shields.
Only minor color palette variations differentiate them, and functionally, they offer the same injection experience.

Insurance Coverage & Cost Considerations

Typically, insurance coverage favors FDA-approved use:
Mounjaro is more likely to be covered when prescribed for diabetes.
Zepbound may face restrictions or higher out-of-pocket costs when prescribed for weight loss.

>> Also read: Ozempic reduces the cost to $499/month

Detailed Comparison Table

Looking for a side-by-side snapshot of Zepbound and Mounjaro?

Whether you're comparing these GLP-1/GIP receptor agonists for weight loss, type 2 diabetes, or both, this data-packed table strips it down to the essentials. Dive in and see how they match up across key categories.

Category	Zepbound	Mounjaro
FDA Approval Indication	Obesity and overweight management (with comorbidities)	Type 2 diabetes management
Year of FDA Approval	2023	2022
Active Ingredient	Tirzepatide	Tirzepatide
Dose Range	2.5 mg to 15 mg once weekly	2.5 mg to 15 mg once weekly
Primary Clinical Purpose	Weight loss	Blood sugar control
GLP-1/GIP Activity	Dual agonist (GLP-1 + GIP)	Dual agonist (GLP-1 + GIP)
Average Weight Loss (in trials)	Up to 22.5% of body weight in SURMOUNT-1 study	Up to 15% of body weight in SURPASS studies
Insulin Sensitivity Impact	Improves insulin sensitivity in patients with obesity	Improves insulin sensitivity in type 2 diabetes patients
Delivery Method	Single-use auto-injector pen, subcutaneous injection	Single-use auto-injector pen, subcutaneous injection
Dosing Frequency	Once weekly	Once weekly
Manufacturer	Eli Lilly	Eli Lilly
Common Side Effects	Nausea, vomiting, diarrhea, constipation, decreased appetite	Nausea, vomiting, diarrhea, constipation, decreased appetite
Insurance Coverage	Variable; often considered for obesity treatment under new formularies	Generally covered under diabetes management plans
Off-Label Use	Not used off-label—approved for weight loss	Frequently used off-label for weight loss

Conclusion: Weighing Real Differences Between Zepbound and Mounjaro

Neither Zepbound nor Mounjaro exists in a vacuum-they're both weekly injectable drugs rooted in tirzepatide, developed by Eli Lilly, and administered via similar pens.

But what separates them lies in their FDA-approved indications, insurance reimbursement pathways, and target patient populations. While the clinical ingredient is the same, patient experience isn't.

Zepbound and Mounjaro are both weekly tirzepatide injections from Eli Lilly, but they differ in approval and patient focus.

Mounjaro (May 2022) is approved for type 2 diabetes, helping control blood sugar while also supporting weight loss.
Zepbound (Nov 2023) is approved for chronic weight management in adults with obesity or overweight plus related conditions, making insurance coverage for weight loss more straightforward.

Both share similar side effects, including nausea, constipation, and fatigue. In practice, doctors tend to prescribe Mounjaro when lowering A1C is the priority, and Zepbound when the goal is significant weight loss in non-diabetic patients. Ultimately, the difference comes down to diagnosis, treatment goals, and insurance coverage-not preference.

Frequenlty Asked Questions When Comparing Zepbound vs. Mounjaro

How do Zepbound and Mounjaro differ in terms of approved use?

Zepbound received FDA approval specifically for chronic weight management, while Mounjaro is approved for improving glycemic control in adults with type 2 diabetes. Both injectables contain tirzepatide as the active ingredient, but their indicated use targets differ. Learn more about how medications like Zepbound work for weight loss management.

Can I switch from Mounjaro to Zepbound if I'm not diabetic?

Yes. If the treatment goal is weight loss rather than glycemic control, physicians may switch patients from Mounjaro to Zepbound. The dosing may change, and the decision depends on a full clinical evaluation. Details on transition protocols and what to discuss with your provider are covered on our telehealth weight loss services page.

Are side effects the same with Zepbound and Mounjaro?

Many side effects overlap due to the identical active ingredient. Gastrointestinal events-such as nausea, diarrhea, vomiting, and constipation-are the most common for both medications. However, Zepbound users focused on weight loss may experience differing side effect intensities depending on dose titration.

Which is better for weight loss: Zepbound or Mounjaro?

Clinical studies show weight loss may occur with both drugs, but Zepbound produces greater average weight reduction. That's because its FDA-approved regimen is optimized for weight management. Meanwhile, Mounjaro's primary indication remains type 2 diabetes.

Do both medications require a prescription from a provider?

They do. Neither Zepbound nor Mounjaro is available over the counter. A licensed healthcare provider must assess your health profile and determine eligibility.

How often do I inject Zepbound or Mounjaro?

Each is a weekly treatment, injected once every seven days. Patients typically choose the same day of the week to maintain consistency.

Do insurance plans cover both medications equally?

Not necessarily. Coverage depends on plan type, diagnosis codes (diabetes or obesity), and the insurer's formulary. Mounjaro may be more widely covered under diabetes benefits, while Zepbound could face more restrictions.